Letrozolo Sun (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens. By inhibiting this conversion, systemic estrogen levels fall, depriving estrogen‑dependent breast cancer cells of the hormonal stimulus needed for proliferation.

The specific dose of Letrozolo Sun is determined by the prescribing clinician based on the patient’s clinical condition, treatment stage and individual factors. Healthcare professionals follow established guidelines to select the appropriate regimen.

Letrozole is contraindicated in pregnancy because it can affect fetal development. It is also not recommended for breastfeeding mothers, as it may pass into breast milk. Women of child‑bearing potential should use effective contraception during treatment.

To request Letrozolo Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, as an aromatase inhibitor, reduces estrogen production, whereas drugs like tamoxifen act as selective estrogen receptor modulators. In postmenopausal patients, aromatase inhibitors such as letrozole generally provide superior disease‑free survival compared with tamoxifen in many clinical trials.

Letrozolo Sun should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain potency throughout its shelf life.

Letrozolo Sun is taken orally, usually as a single tablet once daily, with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and swallow the tablet whole with water.

Serious risks include severe liver injury, osteoporosis‑related fractures, and rare but potentially life‑threatening allergic reactions. Patients should be monitored regularly for liver function, bone health and any signs of hypersensitivity.

Letrozolo Sun is not recommended for premenopausal women, patients with known hypersensitivity to letrozole, those with active liver disease, or individuals who are pregnant or breastfeeding. Clinicians must evaluate each patient’s medical history before initiating therapy.